{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:21:17Z","timestamp":1757625677013,"version":"3.44.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Heat It to Beat It"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03968-y","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:59:38Z","timestamp":1756209578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5065-1416","authenticated-orcid":false,"given":"Luis Felipe","family":"Falla-Zuniga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-9489","authenticated-orcid":false,"given":"Armando","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-3827","authenticated-orcid":false,"given":"Mary Caitlin","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-9172","authenticated-orcid":false,"given":"Felipe","family":"Lopez-Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-7210","authenticated-orcid":false,"given":"Vladislav","family":"Kovalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9778-4208","authenticated-orcid":false,"given":"Sergei","family":"Iugai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-3236","authenticated-orcid":false,"given":"Teresa","family":"Diaz-Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-5660","authenticated-orcid":false,"given":"Vadim","family":"Gushchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"3968_CR1","doi-asserted-by":"publisher","first-page":"1867238","DOI":"10.1155\/2018\/1867238","volume":"2018","author":"YC Lee","year":"2018","unstructured":"Lee YC, Jivraj N, O\u2019Brien C, Chawla T, Shlomovitz E, Buchanan S, et al. Malignant bowel obstruction in advanced gynecologic cancers: an updated review from a multidisciplinary perspective. Obstet Gynecol Int. 2018;2018:1867238.","journal-title":"Obstet Gynecol Int"},{"issue":"3","key":"3968_CR2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/1049909114566225","volume":"33","author":"E Tran","year":"2016","unstructured":"Tran E, Spiceland C, Sandhu NP, Jatoi A. Malignant bowel obstruction in patients with recurrent ovarian cancer. Am J Hosp Palliat Care. 2016;33(3):272\u20135.","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"3968_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/IGC.0b013e318198ff4b","volume":"19","author":"E Sartori","year":"2009","unstructured":"Sartori E, Chiudinelli F, Pasinetti B, Maggino T. Bowel obstruction and survival in patients with advanced ovarian cancer: analysis of prognostic variables. Int J Gynecol Cancer. 2009;19(1):54\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"3968_CR4","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/aogs.14674","volume":"102","author":"K Palsdottir","year":"2023","unstructured":"Palsdottir K, Salehi S, Johansson H, Groes-Kofoed N, Falconer H, Joneborg U. Incidence of and survival after surgical intervention for bowel obstruction in women with advanced ovarian cancer. Acta Obstet Gynecol Scand. 2023;102(12):1653\u201360.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"3968_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ygyno.2012.12.028","volume":"129","author":"SJ Mooney","year":"2013","unstructured":"Mooney SJ, Winner M, Hershman DL, Wright JD, Feingold DL, Allendorf JD, et al. Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol. 2013;129(1):107\u201312.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3968_CR6","doi-asserted-by":"publisher","first-page":"20180101","DOI":"10.1515\/pp-2018-0101","volume":"3","author":"BJ Moran","year":"2018","unstructured":"Moran BJ, Tzivanakis A. The concept of Obstruction-Free survival as an outcome measure in advanced colorectal cancer management. Pleura Peritoneum. 2018;3(1):20180101.","journal-title":"Pleura Peritoneum"},{"issue":"10","key":"3968_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.12968\/ijpn.2001.7.10.9904","volume":"7","author":"B Gwilliam","year":"2001","unstructured":"Gwilliam B, Bailey C. The nature of terminal malignant bowel obstruction and its impact on patients with advanced cancer. Int J Palliat Nurs. 2001;7(10):474\u201381.","journal-title":"Int J Palliat Nurs"},{"key":"3968_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/IJWH.S366680","volume":"14","author":"E Gonzalez-Ochoa","year":"2022","unstructured":"Gonzalez-Ochoa E, Alqaisi HA, Bhat G, Jivraj N, Lheureux S. Inoperable bowel obstruction in ovarian cancer: prevalence, impact and management challenges. Int J Womens Health. 2022;14:1849\u201362.","journal-title":"Int J Womens Health"},{"key":"3968_CR9","unstructured":"Society TAC. SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2023. Available from https:\/\/seer.cancer.gov\/explorer\/."},{"issue":"1","key":"3968_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/IGC.0000000000000843","volume":"27","author":"A Gadducci","year":"2017","unstructured":"Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, et al. Patterns of recurrence and clinical outcome of patients with stage IIIC to stage IV epithelial ovarian cancer in complete response after primary debulking surgery plus chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery: an Italian multicenter retrospective study. Int J Gynecol Cancer. 2017;27(1):28\u201336.","journal-title":"Int J Gynecol Cancer"},{"key":"3968_CR11","doi-asserted-by":"crossref","unstructured":"Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017;28(4):727\u201332.","DOI":"10.1093\/annonc\/mdw663"},{"issue":"2","key":"3968_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000521239","volume":"38","author":"A Bhatt","year":"2022","unstructured":"Bhatt A, Glehen O. Hyperthermic intraperitoneal chemotherapy in the treatment armamentarium of epithelial ovarian cancer: time to end the dichotomy. Visc Med. 2022;38(2):109\u201319.","journal-title":"Visc Med"},{"issue":"3","key":"3968_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, van Schagen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"6","key":"3968_CR14","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ejso.2021.01.013","volume":"47","author":"S Sinukumar","year":"2021","unstructured":"Sinukumar S, Damodaran D, Ray M, Mehta S, Paul L, Bhatt A. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC\/IVA epithelial ovarian cancer. Eur J Surg Oncol. 2021;47(6):1427\u201333.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"3968_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.asjsur.2020.05.010","volume":"44","author":"FC Chow","year":"2021","unstructured":"Chow FC, Yip J, Foo DC, Wei R, Choi HK, Ng KK, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review. Asian J Surg. 2021;44(1):221\u20138.","journal-title":"Asian J Surg"},{"issue":"2","key":"3968_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ygyno.2020.12.029","volume":"160","author":"TH Dellinger","year":"2021","unstructured":"Dellinger TH, Han ES. State of the science: the role of HIPEC in the treatment of ovarian cancer. Gynecol Oncol. 2021;160(2):364\u20138.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3968_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","volume":"108","author":"EL Eisenhauer","year":"2008","unstructured":"Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008;108(2):276\u201381.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3968_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","volume":"114","author":"DS Chi","year":"2009","unstructured":"Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26\u201331.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3968_CR19","doi-asserted-by":"publisher","first-page":"107948","DOI":"10.1016\/j.ejso.2023.107948","volume":"50","author":"A Nikiforchin","year":"2024","unstructured":"Nikiforchin A, Sardi A, King MC, Baron E, Lopez-Ramirez F, Falla-Zuniga LF, et al. Collaborative expertise of gynecological and surgical oncologists in managing advanced epithelial ovarian cancer. Eur J Surg Oncol. 2024;50(2):107948.","journal-title":"Eur J Surg Oncol"},{"issue":"20","key":"3968_CR20","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3968_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and Pseudomyxoma peritonei syndrome? Lancet. 2006;7(1):69\u201376.","journal-title":"Lancet"},{"key":"3968_CR22","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"issue":"15","key":"3968_CR23","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","volume":"22","author":"M Markman","year":"2004","unstructured":"Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22(15):3120\u20135.","journal-title":"J Clin Oncol"},{"issue":"9375","key":"3968_CR24","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099\u2013106.","journal-title":"Lancet"},{"issue":"1","key":"3968_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13048-020-00681-0","volume":"13","author":"S Piatek","year":"2020","unstructured":"Piatek S, Panek G, Lewandowski Z, Bidzinski M, Piatek D, Kosinski P, et al. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer. J Ovarian Res. 2020;13(1):102.","journal-title":"J Ovarian Res"},{"issue":"8","key":"3968_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"D Ho","year":"2011","unstructured":"Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1\u201328.","journal-title":"J Stat Softw"},{"issue":"1","key":"3968_CR27","first-page":"CD002764","volume":"2016","author":"SE Cousins","year":"2016","unstructured":"Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and Gastrointestinal cancer. Cochrane Database Syst Rev. 2016;2016(1):CD002764.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3968_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0046-8177(88)80316-2","volume":"19","author":"PM Dvoretsky","year":"1988","unstructured":"Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Stoler MH, Beecham JB, et al. Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol. 1988;19(1):57\u201363.","journal-title":"Hum Pathol"},{"issue":"3","key":"3968_CR29","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1245\/s10434-020-09064-7","volume":"28","author":"Y Berger","year":"2021","unstructured":"Berger Y, Schuitevoerder D, Vining CC, Alpert L, Fenton E, Hindi E, et al. Novel application of iterative hyperthermic intraperitoneal chemotherapy for unresectable peritoneal metastases from High-Grade appendiceal Ex-Goblet adenocarcinoma. Ann Surg Oncol. 2021;28(3):1777\u201385.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"3968_CR30","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1245\/s10434-019-07507-4","volume":"26","author":"JM Baumgartner","year":"2019","unstructured":"Baumgartner JM, Marmor R, Hsu A, Veerapong J, Kelly KJ, Lowy AM. Obstruction-Free survival following operative intervention for malignant bowel obstruction in appendiceal cancer. Ann Surg Oncol. 2019;26(11):3611\u20137.","journal-title":"Ann Surg Oncol"},{"key":"3968_CR31","doi-asserted-by":"crossref","unstructured":"Lopez-Ramirez F, Sardi A, Studeman K, King MC, Falla Zuniga LF, Nikiforchin A et al. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma. Eur J Surg Oncol. 2023;49(8):1495\u2013503.","DOI":"10.1016\/j.ejso.2023.03.230"},{"issue":"5","key":"3968_CR32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20(5):1248\u201359.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3968_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ygyno.2013.06.017","volume":"130","author":"N Rodriguez","year":"2013","unstructured":"Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of gynecologic oncology group (GOG) 182. Gynecol Oncol. 2013;130(3):487\u201392.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"3968_CR34","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s10147-020-01714-w","volume":"25","author":"S Tate","year":"2020","unstructured":"Tate S, Nishikimi K, Matsuoka A, Shozu M. Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence. Int J Clin Oncol. 2020;25(9):1726\u201335.","journal-title":"Int J Clin Oncol"},{"key":"3968_CR35","unstructured":"Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45\u201357."},{"key":"3968_CR36","doi-asserted-by":"crossref","unstructured":"Falla-Zuniga LF, Sardi A, King MC, Nikiforchin A, Lopez-Ramirez F, Barakat P et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) vs. postoperative intraperitoneal (IP) chemotherapy\u2014impact on health-related quality of life in primary ovarian cancer patients after cytoreductive surgery. Surg Oncol Insight. 2024;1(3):100073.","DOI":"10.1016\/j.soi.2024.100073"},{"issue":"13","key":"3968_CR37","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460\u20136.","journal-title":"J Clin Oncol"},{"key":"3968_CR38","doi-asserted-by":"crossref","unstructured":"Acs M, Herold Z, Szasz AM, Mayr M, Hausler S, Piso P. Prolonged exposition with hyperthermic intraperitoneal chemotherapy (HIPEC) May provide survival benefit after cytoreductive surgery (CRS) in advanced primary epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancers (Basel). 2022;14(14).","DOI":"10.3390\/cancers14143301"},{"issue":"1","key":"3968_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","volume":"127","author":"KM Esselen","year":"2012","unstructured":"Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012;127(1):51\u20134.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3968_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","volume":"124","author":"EJ Tanner","year":"2012","unstructured":"Tanner EJ, Black DR, Zivanovic O, Kehoe SM, Dao F, Konner JA, et al. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecol Oncol. 2012;124(1):59\u201362.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"3968_CR41","first-page":"1","volume":"29","author":"M Ceresoli","year":"2018","unstructured":"Ceresoli M, Verrengia A, Montori G, Busci L, Coccolini F, Ansaloni L, et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: A propensity score based case-control study. J Gynecologic Oncol. 2018;29(3):1\u201310.","journal-title":"J Gynecologic Oncol"},{"issue":"7","key":"3968_CR42","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/jso.25703","volume":"120","author":"D Biacchi","year":"2019","unstructured":"Biacchi D, Accarpio F, Ansaloni L, Macri A, Ciardi A, Federici O, et al. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC. J Surg Oncol. 2019;120(7):1208\u201319.","journal-title":"J Surg Oncol"},{"issue":"9","key":"3968_CR43","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","volume":"23","author":"P Amate","year":"2013","unstructured":"Amate P, Huchon C, Dessapt AL, Bensaid C, Medioni J, Le Frere Belda MA, et al. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013;23(9):1590\u20136.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"3968_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: A randomized clinical trial. JAMA Surg. 2022;157(5):374\u201383.","journal-title":"JAMA Surg"},{"issue":"4","key":"3968_CR45","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"PA Cascales Campos","year":"2022","unstructured":"Cascales Campos PA, Gonz\u00e1lez Gil A, Gil G\u00f3mez E, Gonz\u00e1lez S\u00e1nchez R, Mart\u00ednez Garc\u00eda J, Alonso Romero JL, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A phase 3 clinical trial. Ann Surg Oncol. 2022;29(4):2617\u201325.","journal-title":"Ann Surg Oncol"},{"key":"3968_CR46","doi-asserted-by":"publisher","first-page":"809773","DOI":"10.3389\/fonc.2022.809773","volume":"12","author":"A Souadka","year":"2022","unstructured":"Souadka A, Essangri H, Majbar MA, Benkabbou A, Boutayeb S, You B, et al. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in ovarian cancer: an umbrella review of Meta-Analyses. Front Oncol. 2022;12:809773.","journal-title":"Front Oncol"},{"issue":"3","key":"3968_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","volume":"167","author":"SI Kim","year":"2022","unstructured":"Kim SI, Kim JH, Lee S, Cho H, van Driel WJ, Sonke GS, et al. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis. Gynecol Oncol. 2022;167(3):547\u201356.","journal-title":"Gynecol Oncol"},{"key":"3968_CR48","doi-asserted-by":"crossref","unstructured":"Della Corte L, Conte C, Palumbo M, Guerra S, Colacurci D, Riemma G et al. Hyperthermic intraperitoneal chemotherapy (HIPEC): new approaches and controversies on the treatment of advanced epithelial ovarian cancer-systematic review and meta-analysis. J Clin Med. 2023;12(22):7012.","DOI":"10.3390\/jcm12227012"},{"key":"3968_CR49","doi-asserted-by":"crossref","unstructured":"El Hajj H, Vanseymortier M, Hudry D, Bogart E, Abdeddaim C, Leblanc E et al. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery. ESMO Open. 2021;6(2):100098.","DOI":"10.1016\/j.esmoop.2021.100098"},{"issue":"4","key":"3968_CR50","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1245\/s10434-022-12957-4","volume":"30","author":"SN Gregory","year":"2023","unstructured":"Gregory SN, Ryan CE, Hernandez JM, Sonke GS, Aronson SL, Zivanovic O, et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) (OVHIPEC-2). Ann Surg Oncol. 2023;30(4):1950\u20132.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"3968_CR51","doi-asserted-by":"publisher","first-page":"8115","DOI":"10.1245\/s10434-023-13932-3","volume":"30","author":"A Bhatt","year":"2023","unstructured":"Bhatt A, Glehen O, Zivanovic O, Brennan D, Nadeau C, Van Driel W, et al. The 2022 PSOGI international consensus on HIPEC regimens for peritoneal malignancies: epithelial ovarian cancer. Ann Surg Oncol. 2023;30(13):8115\u201337.","journal-title":"Ann Surg Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03968-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03968-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03968-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:53:15Z","timestamp":1757443995000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03968-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3968"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03968-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"type":"electronic","value":"1477-7819"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has been approved by Mercy Medical Center Institutional Review Board (IRB# 2014-17; 1230783).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The informed consent of this study has been obtained from patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"318"}}